This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

RG7990

Roche Holding AG

Drug Names(s): RG 7990, RG-7990, BITS7201A, BITS 7201A, BITS-7201A

Description: RG-7990 is a monoclonal antibody targeting the IL13/17 receptors.

Deal Structure: Novimmune and Genentech
In July, 2010, NovImmune announced that it entered into an exclusive licensing agreement with Genentech for a proprietary anti-IL-17 fully human monoclonal antibody, and access to back-up antibodies. The anti-IL-17 antibody was generated by NovImmunes research team and is currently in late preclinical development. Under the terms of the agreement NovImmune will receive an upfront payment and is eligible to receive clinical milestones and royalties on sales. Full financial terms have not been disclosed.

Partners: NovImmune SA


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug